Lecanemab for Early Alzheimer’s Disease

Key Stakeholder Organizations

ICER receives input on its reviews from patients and their families, patient advocacy organizations, clinicians, clinical societies, insurers, and drugmakers. We invite the public to submit recommendations for key stakeholders in any of these categories. The following is a list of organizations from which ICER has requested input as well as those that have provided public comments during the review. None of these individuals or organizations is responsible for the final content of ICER’s report, and it should not be assumed that they support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of key dates and opportunities for input on this project, please visit ICER’s website.

- Alliance for Aging Research
- Alzheimer’s Association
- The Alzheimer’s Drug Discovery Foundation
- The American Geriatrics Society
- Biogen Inc.
- Black Women’s Health Imperative
- California Chronic Care Coalition
- Eisai Inc.
- Eli Lilly and Company
- GE Healthcare
- Genentech, A Member of the Roche Group
- Global Alzheimer’s Platform Foundation
- Healthy Men Inc.
- Institute for Patient Access
- National Minority Quality Forum
- Partnership to Fight Chronic Disease
- Partnership to Improve Patient Care
- Point32Health
- Prime Therapeutics
- RetireSafe
- Society for Women’s Health Research
- UsAgainstAlzheimer’s
- Voices of Alzheimer’s